Updated SCAI guidance includes Coronary IVL as a treatment option in all U.S. cath labs regardless of surgical backup status.
Welcome to The Catalyst
Change isn't quick. Unless it's when you experience Intravascular Lithotripsy (IVL) for the first time. Stay apprised of our latest news and insights while discovering how a simple and intuitive tool can be The Catalyst to change the way you think about calcium modification.
Updated SCAI guidance includes Coronary IVL as a treatment option in all U.S. cath labs regardless of surgical backup status.
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
Dear Interventional Community,
Topics: SWAV News
CMS Corrects Error for IVL Procedures in ASC Setting – Retroactive TPT Payment Eligible for 2022
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2, Reimbursement
Für eine deutschsprachige Version klicken Sie HIER
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2, Reimbursement
Verbesserte Kostenerstattung für koronare IVL in Deutschland
For an English language version, click HERE
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2, Reimbursement
Dr. Misty Humphries reviews the sex specific analysis from the Disrupt PAD III Observational Study while at VIVA 2022. Because females often present with more difficult characteristics for endovascular therapy, this analysisof 1,373 patients aimed to illustrate that IVL can safely and effectively modify calcium regardless of gender. Dr. Humphries shares that despite women having smaller vessels, the complication rate was extremely low, with no significant difference in embolization or perforations when using Shockwave IVL to treat PAD.
Check out the presentation below and hear from Dr. Humphries on the importance of this ‘real-world’ data set in the treatment of heavily calcified PAD.
Topics: Peripheral IVL
Calcified hostile access can be an exclusion criteria for endograft delivery and has been associated with both perioperative and long term morbidity and mortality…this is changing! Join the discussion between Drs Bosiers, Fazzini and Isernia and hear how IVL is changing the boundaries in their daily practice for endograft delivery by changing vessel compliance, providing excellent luminal gain and improving patient safety, simplifying the challenges raised by hostile calcified access.
Topics: Peripheral IVL
Tune in for session 2 of Shockweek on Vascupedia as Dr. Elias Noory treats multiple highly calcified femoropopliteal lesions with IVL. During the session, our expert panel of Drs Lorenzo Patrone, Enrique Alejandre Lafont, Bella Huasen and Thanos Saratzis discuss how IVL can overcome the pitfalls of CLTI treatment by changing vessel compliance to reduce procedural complications. Dr. Noory and the panel also share pearls of wisdom on how to optimize your IVL strategy to get the best outcomes for patients and crack the calcium conundrum.
Topics: Peripheral IVL
Shockwave partnered with Vascupedia to host a week-long virtual event with live cases and panel discussions. Session one focuses on ‘A New Approach to Tackling Calcified Disease in Large Vessels’. In the session, Dr. Elias Noory presents a live case from Bad Krozingen, Germany and is accompanied by an esteemed panel of Drs Arko, Bisdas and Coscas who discuss the role of endovascular treatment for common femoral disease.
Tune in to hear from the experts on how IVL is changing the treatment paradigm for heavily calcified CFA disease by providing a safe and effective treatment for calcified vessels. See how Dr. Noory utilizes IVL to achieve increased vessel compliance and luminal gain to enable a ‘leave-nothing-behind’ strategy.
For the full video from Day 1 click here: https://vascupedia.com/presentation/a-new-approach-to-tackling-calcified-disease-in-large-vessels-shockweek-day-1/
Topics: Peripheral IVL
Just five years ago, we were a start-up, commencing the launch of our pioneering treatment for calcified cardiovascular disease. Today we are a public company with customers in over 60 countries and a robust pipeline of technologies in various stages of development. Backed by solid clinical results, our intravascular lithotripsy (IVL) system has been used to treat more than 120,000 patients worldwide and we have every reason to believe it will help millions.
Topics: IVL Technology, SWAV News
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
